Pieris and Daiichi Sankyo sign EUR207m Anticalin deal
Freising – German drug development pioneer Pieris AG will use its Anticalin scaffold technology to develop high affinity binders against two targets from Daiichi Sankyo Company Ltd (Tokyo). Pieris will receive EUR7 million upfront, plus research funding, preclinical, regulatory and commercial milestones, while Daiichi Sankyo will be responsible for clinical development and marketing of the Anticalin compounds. In case of full commercialisation, Pieris could make EUR100 million for each target plus mid- to mid-high single digit royalties on sales. Under the terms of the agreement, Daiichi Sankyo will have exclusive global marketing rights. Anticalins are recombinantly engineered lipocalins, endogenous low-molecular weight human proteins that naturally bind, store and transport a wide spectrum of molecules.